Kripto Paraları Ara

Trend Kripto Paralar

CoinRithm

Şirket

Tüzel Kişilik
Bees-x Limited
Şirket Numarası
13308136
Kuruluş Yeri
England and Wales
Kayıtlı Ofis
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm, Bees-x Limited tarafından işletilen bir bilgi ve araştırma hizmetidir. Düzenlenmiş faaliyetleri yürütmek üzere Financial Conduct Authority (FCA) tarafından yetkilendirilmemiştir ve bu sitedeki hiçbir içerik finansal tavsiye değildir.

Piyasalar

Kripto ParalarTahmin PiyasalarıHaberler

Ajansal İşlem

Ajansal İşlemAgent ArenaStudio'da OluşturGeliştirici kitiMCP belgeleri

İşlem

Ticaret SimülasyonuPortföyİzleme ListesiKontrol Paneli

Öğren

YazılarLiglerSınıflar içinMetodoloji

Şirket

HakkımızdaDestekle İletişimSSSKullanım ŞartlarıGizlilik PolitikasıÇerez PolitikasıFeragatname

Sosyal Medya

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Tüm hakları saklıdır.
Google Play'de edininApp Store'dan İndirin
  • Ana Sayfa
  • PiyasalarTahmin Piyasaları
  • Haberler
  • Kontrol Paneli
  1. Tahmin Piyasaları
  2. Health & Medicine
  3. Phase 3 Result: Sublingual Minoxidil by Samson Clinical Operations (June 2026)
Phase 3 Result: Sublingual Minoxidil by Samson Clinical Operations (June 2026)

Phase 3 Result: Sublingual Minoxidil by Samson Clinical Operations (June 2026)

2.0% (24s)One-OffHealth & MedicineBilim11g
KalshiKalshiKullanılabilirliği kontrol etKYC gerekli%2 ücret
Güncel ima edilen olasılık
No Results
No Results 68%+2.0%
5 seçenek arasında lider
Piyasa kalitesi

49 / 100

Düşük kalite
24s Hacim

₺361,5

Likidite

₺574,3

Düşük likidite
Alis / Satis

66.0% / 67.0%

Spread

1.5%

Dar spread
Piyasa verileri

6 dakika önce guncellendi

10 Haz 26 0:001 Tem 26 3:59

Trendler

Sonuç24sOlasılık

Seçilen sonuç

No Results68%

Kurallar

If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Success results in June 2026, the market resolves to Yes.

Kalshi
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Mixed results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Failure results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Ambiguous results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports No Results results in June 2026, the market resolves to Yes.

İlgili Piyasalar

Manifold Markets

Testosterone unscheduled/rescheduled more permissively in US by end of 2028?

₺53,4 B
Evet: 22.2%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Delivery Ritalin exists in one year?

₺23,2 B
Evet: 7.5%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Will there be a cure for schizophrenia before 2032?

₺23,2 B
Evet: 11.8%Manifold MarketsMANIFOLD MARKETS
When will Beam Therapeutics submit a BLA for Risto-cel?

When will Beam Therapeutics submit a BLA for Risto-cel?

₺6,2
before November: 37%KalshiKALSHI
When will Intellia Therapeutics submit a BLA for Lonvo-z?

When will Intellia Therapeutics submit a BLA for Lonvo-z?

₺2,1
before October: 50%KalshiKALSHI
When will Compass Pathways submit a NDA for COMP360 psilocybin?

When will Compass Pathways submit a NDA for COMP360 psilocybin?

₺1,4
before November: 65%KalshiKALSHI

Bu konularda aktif

BitcoinBTC$62,603.43-3.00%EthereumETH$1,694.77-3.21%SolanaSOL$68.35-4.92%DogecoinDOGE$0.0824-3.14%XRPXRP$1.13-4.54%BNBBNB$573.59-2.96%

İlgili Haberler

AI-Powered Chemist GPT-5.4 Boosts Drug Reaction YieldsBlockchain.NewsNVIDIA BioNeMo Enables LoRA Fine-Tuning for Biotech ModelsBlockchain.NewsEthereum Researcher: Quantum-Proof Accounts Possible for $0.07Blockchain.NewsIBM Launches ffsim to Accelerate Fermionic Circuit SimulationsBlockchain.NewsAnthropic Targets AI-Driven Biology with gget Virus ToolBlockchain.NewsAnthropic’s Claude Tackles Chemistry with NMR Structure AnalysisBlockchain.News

Kurallar

If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Success results in June 2026, the market resolves to Yes.

Kalshi
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Mixed results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Failure results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Ambiguous results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports No Results results in June 2026, the market resolves to Yes.